Jiang Ai-Ying, Zhang Jing, Luo Hai-Long, Gao Feng, Lv Yu-Feng
Department of Respiratory Medicine, The Affiliated Hongqi Hospital of Mudanjiang Medical University Department of Anatomy, Mudanjiang Medical University Department of Neurology, The Affiliated Hongqi Hospital of Mudanjiang Medical University Department of Anesthesiology, Mudanjiang Hospital of Traditional Chinese Medicine, Mudanjiang, China.
Medicine (Baltimore). 2018 Apr;97(15):e0312. doi: 10.1097/MD.0000000000010312.
This study aimed to explore the effect and toxicity of icotinib and whole-brain radiotherapy (IWBRT) for the treatment of brain metastases from nonsmall cell lung cancer (BMNSCLC) with epidermal growth factor receptor (EGFR)-mutant among Chinese Han population.A total of 55 patients with EGFR-mutant BMNSCLC were included. They received orally icotinib (125 mg/tablet, 125 mg each time, 3 times daily) until disease progression. In addition, they also underwent whole-brain radiotherapy (3-Gy fractions once daily, 5 days weekly for a total dose of 30 Gy) in an attempt to extend their survival time. The outcomes consisted of complete response (CR), partial response (PR), stable disease (SD), progress disease (PD), overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). In addition, toxicity was also recorded in this study.The CR, PR, SD, PD, ORR, PFS, and OS were 38.2%, 52.8%, 5.4%, 3.6%, 90.1%, 12.5%, and 48.0% months, respectively. In addition, mild toxicity was observed in this study.This study demonstrated that IWBRT is efficacious with acceptable toxicity for patients with EGFR-mutant BMNSCLC among Chinese Han population.
本研究旨在探讨埃克替尼与全脑放疗（IWBRT）联合治疗中国汉族人群表皮生长因子受体（EGFR）突变的非小细胞肺癌脑转移（BMNSCLC）的疗效及毒性。共纳入55例EGFR突变的BMNSCLC患者。他们口服埃克替尼（125mg/片，每次125mg，每日3次）直至疾病进展。此外，他们还接受了全脑放疗（每次3Gy，每日1次，每周5天，总剂量30Gy），以期延长生存时间。观察指标包括完全缓解（CR）、部分缓解（PR）、疾病稳定（SD）、疾病进展（PD）、总缓解率（ORR）、无进展生存期（PFS）和总生存期（OS）。此外，本研究还记录了毒性反应。CR、PR、SD、PD、ORR、PFS和OS分别为38.2%、52.8%、5.4%、3.6%、90.1%、12.5个月和48.0个月。此外，本研究观察到轻度毒性反应。本研究表明，对于中国汉族EGFR突变的BMNSCLC患者，IWBRT疗效显著且毒性可接受。
